Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer

21 Sept 2017

Abstract excerpt

// Huogang Wang 1, 2, 3, * , Bo Hong 1, 3, * , Xuemin Li 1, 3 , Ke Deng 1, 2, 3 , Hong Li 1, 3 , Vivian Wai Yan Lui 4 and Wenchu Lin 1, 3 1 High Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei 230031, Anhui, P.R. China 2 University of Science and Technology of China, Hefei 230036, Anhui, P.R. China 3 Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Research Studies
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29156797
DOI: 10.18632/oncotarget.21146

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancerPMID 29156797Read ↗

Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell LinesSemantic proximity Read ↗

MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expressionSemantic proximity Read ↗

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancerSemantic proximity Read ↗

Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737Semantic proximity Read ↗

Co-targeting BCL-X <sub>L</sub> and MCL-1 with DT2216 and AZD8055 synergistically inhibits small-cell lung cancer growth without causing on-target toxicities in miceSemantic proximity Read ↗

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant gliomaSemantic proximity Read ↗

Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 InhibitorsSemantic proximity Read ↗

Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancerSemantic proximity Read ↗

BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer CellsSemantic proximity Read ↗

Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung CancerSemantic proximity Read ↗

Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.Semantic proximity Read ↗

Dual inhibition of BCL2L1 and MCL1 is highly effective against RET fusion-positive or MET exon 14 skipping mutation-positive lung adenocarcinoma cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.